Lenvatinib, Tislelizumab Combined with Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma

This study tests whether adding lenvatinib (a drug that blocks tumor blood vessel growth) and tislelizumab (an immunotherapy drug) to standard chemotherapy (gemcitabine and cisplatin) can improve treatment outcomes for people with advanced or unresectable cholangiocarcinoma — a cancer of the bile ducts. This combination aims to attack the cancer through multiple pathways at once. **You may be eligible if...** - Your bile duct cancer has been confirmed by biopsy and cannot be surgically removed - You are in good health (ECOG 0–1) with an expected survival of more than 12 weeks - You have not previously received immunotherapy (anti-PD-1/PD-L1 or anti-CTLA-4 drugs) - Your blood counts and organ function tests are within acceptable ranges **You may NOT be eligible if...** - You have already received immunotherapy for this cancer - You have uncontrolled high blood pressure or serious heart conditions - You have active autoimmune disease - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.